Psychiatric Orders in Psychoanalytic Treatment of ASD

Yang I. Pachankis, PhD

Status: Active, not recruiting

Conditions: Depression and Suicide; ADHD - Combined Type; Agoraphobia With Panic Attacks; Anxiety Disorders; Stockholm Syndrome; Panic Disorder With Agoraphobia, Severe Agoraphobic Avoidance and Mild Panic Attacks; Depression, Reactive; OCD; Grief; Separation Insecurity; Borderline Personality Disorder; Depression; Psychoneurotic; PTSD; Depression, Anxiety; Depression, Unipolar; Autism Spectrum Disorder High-Functioning; Depression Anxiety Disorder; Avoidant Personality Disorder; Social Anxiety Disorder

Treatments: Diagnostic Test: Psychoanalysis; Behavioral: Cognitive Behavioral Therapy; Drug: sertraline 50mg; Drug: Duloxetine 20 MG

Study type: Observational

Funder types: Other

Identifiers

NCT05930912

ASD-000000 (Other Grant/Funding Number)

ASD-Psy-000

Details and patient eligibility

About

Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments.

The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits.

The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations.

The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.

Enrollment: 1 patient

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Persons with ASD.

Exclusion criteria

• Severe ASD cases with central nerve system complications.

Trial design

1 participants in 1 patient group

Participant Case

Description:

The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.

Treatment:

Drug: Duloxetine 20 MG

Drug: sertraline 50mg

Behavioral: Cognitive Behavioral Therapy

Diagnostic Test: Psychoanalysis